Retatrutide Side Effects: Safety Signals and Warnings
Retatrutide safety concerns are compound-specific. The main listed side effects are Nausea, Diarrhea, and Vomiting. The main warning signals are Not yet approved for clinical use - investigational only, Risk of gastrointestinal adverse events, especially during dose escalation, and Potential risk of thyroid C-cell tumors based on GLP-1 class warnings.
Direct Answer
Retatrutide has the largest sponsor-reported Phase 3 weight-loss signal in the database and now has positive results across five Phase 3 studies. It remains unapproved, and the new results are not yet fully peer reviewed, so tirzepatide remains the evidence-backed approved choice while retatrutide is the leading late-stage candidate.
- Evidence grade
- Level B
- Research status
- Phase 3
- Category
- Weight Loss & Metabolic
- Evidence context
- Weight loss research, obesity pharmacology, metabolic dysfunction-associated steatotic liver disease
Reported Side Effects
- Nausea
- Diarrhea
- Vomiting
- Decreased appetite
- Constipation
- Injection site reactions
Warnings
- Not yet approved for clinical use - investigational only
- Risk of gastrointestinal adverse events, especially during dose escalation
- Potential risk of thyroid C-cell tumors based on GLP-1 class warnings
- Should not be used in patients with a personal or family history of medullary thyroid carcinoma
Known or Plausible Interactions
- Insulin and sulfonylureas (increased hypoglycemia risk)
- Oral medications (delayed gastric emptying may alter absorption)
Regulatory Context
Investigational and not FDA-approved. Lilly has reported five positive Phase 3 studies and plans a biologics license application in the first quarter of 2027. Retatrutide has no approved retail or compounded version; products sold outside authorized trials are unapproved.
Evidence Snapshot
| Evidence grade | Level B |
|---|---|
| Research status | Phase 3 |
| Best supported outcomes | Body Weight Reduction (Level B), Glycemic Control (Level B), Hepatic Fat Reduction (Level B), and Gastrointestinal Side Effects (Level B) |
| Primary citation count | 5 |
| Last reviewed | 2026-08-27 |
Quick Answers
What are the side effects of Retatrutide?
Retatrutide safety concerns are compound-specific. The main listed side effects are Nausea, Diarrhea, and Vomiting. The main warning signals are Not yet approved for clinical use - investigational only, Risk of gastrointestinal adverse events, especially during dose escalation, and Potential risk of thyroid C-cell tumors based on GLP-1 class warnings.
What is the evidence level for Retatrutide?
Retatrutide is rated Level B. Its current research status is Phase 3.
What is Retatrutide best known for?
Weight loss research, obesity pharmacology, metabolic dysfunction-associated steatotic liver disease.
Where can I read the full Retatrutide evidence review?
The full evidence review is available at https://examinepeptides.com/library/retatrutide.
Related Guides
How to Cite This Page
ExaminePeptides. "Retatrutide Side Effects: Safety Signals and Warnings." Last reviewed 2026-08-27. https://examinepeptides.com/answers/retatrutide-side-effects-safety/
This static answer page is built for fast indexing and direct citation. It summarizes the matching full evidence review and links back to primary sources where the source database includes them.